Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01905631 · ClinicalTrials.gov registry record · Phase 2
Blinded, Randomized Study Evaluating Aurstat Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus
A Phase 2 study, sponsored by The Center for Clinical and Cosmetic Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT01905631 is a Phase 2 study that has completed, run by The Center for Clinical and Cosmetic Research. The registered enrollment target is 30 participants.
The verdict
NCT01905631, a Phase 2 study, has completed, sponsored by The Center for Clinical and Cosmetic Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
To demonstrate the ability of Aurstat to reduce pruritus in subjects with mild to moderate atopic dermatitis. Efficacy results will be based on subject assessment, IGA, and photographic evidence based on ordinal scales for tolerability.
Interventions
- DRUG Aurstat Anti-Itch Hydrogel (Aurstat)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2013-07 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01905631
The ClinicalTrials.gov registry entry for NCT01905631 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Center for Clinical and Cosmetic Research, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aurstat Anti-Itch Hydrogel (Aurstat) is the first listed.
NCT01905631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01905631 about?
NCT01905631 is a clinical study titled "Blinded, Randomized Study Evaluating Aurstat Versus Control in the Treatment of Atopic Dermatitis Associated Pruritus". To demonstrate the ability of Aurstat to reduce pruritus in subjects with mild to moderate atopic dermatitis. Efficacy results will be based on subject assessment, IGA, and photographic evidence based on ordinal scales for tolerability.
What is the current status of trial NCT01905631?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2013-07. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01905631?
The interventions under investigation include: Aurstat Anti-Itch Hydrogel (Aurstat) (DRUG).
Who is sponsoring clinical trial NCT01905631?
This trial is sponsored by The Center for Clinical and Cosmetic Research, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.